Harvey Investment Co. LLC cut its position in Allergan PLC. (NYSE:AGN) by 26.7% during the second quarter, Holdings Channel reports. The institutional investor owned 3,502 shares of the company’s stock after selling 1,277 shares during the period. Harvey Investment Co. LLC’s holdings in Allergan PLC. were worth $851,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Verde Servicos Internacionais S.A. increased its position in shares of Allergan PLC. by 22.0% in the first quarter. Verde Servicos Internacionais S.A. now owns 101,977 shares of the company’s stock worth $24,364,000 after buying an additional 18,387 shares in the last quarter. Horan Capital Management increased its position in shares of Allergan PLC. by 21.4% in the first quarter. Horan Capital Management now owns 38,717 shares of the company’s stock worth $9,250,000 after buying an additional 6,836 shares in the last quarter. BKD Wealth Advisors LLC purchased a new position in shares of Allergan PLC. during the first quarter worth approximately $219,000. American National Bank increased its position in shares of Allergan PLC. by 0.6% in the first quarter. American National Bank now owns 15,233 shares of the company’s stock worth $3,640,000 after buying an additional 95 shares in the last quarter. Finally, Atria Investments LLC increased its position in shares of Allergan PLC. by 35.1% in the first quarter. Atria Investments LLC now owns 7,310 shares of the company’s stock worth $1,747,000 after buying an additional 1,900 shares in the last quarter. Institutional investors and hedge funds own 84.77% of the company’s stock.

Shares of Allergan PLC. (NYSE AGN) traded up 0.29% on Friday, reaching $232.88. The company’s stock had a trading volume of 1,820,899 shares. The stock has a 50-day moving average price of $245.93 and a 200-day moving average price of $238.13. Allergan PLC. has a 1-year low of $184.50 and a 1-year high of $256.80. The company has a market capitalization of $77.85 billion, a price-to-earnings ratio of 7.10 and a beta of 1.16.

Allergan PLC. (NYSE:AGN) last issued its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. Allergan PLC.’s revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $3.35 earnings per share. On average, equities research analysts forecast that Allergan PLC. will post $16.27 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a dividend of $0.70 per share. The ex-dividend date is Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.20%. Allergan PLC.’s dividend payout ratio is presently 9.95%.

TRADEMARK VIOLATION NOTICE: This piece was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/08/12/harvey-investment-co-llc-sells-1277-shares-of-allergan-plc-agn.html.

AGN has been the topic of a number of research analyst reports. Citigroup Inc. restated a “focus list” rating and set a $261.27 price target (up previously from $184.50) on shares of Allergan PLC. in a research note on Friday, April 21st. Royal Bank Of Canada boosted their price target on Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 10th. Goldman Sachs Group, Inc. (The) lowered Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price target on the stock. in a research note on Wednesday, May 10th. UBS AG restated a “buy” rating and set a $275.00 price target on shares of Allergan PLC. in a research note on Monday, May 15th. Finally, Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a research note on Thursday, May 25th. Eight research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Allergan PLC. has an average rating of “Buy” and an average target price of $274.49.

In other news, Director Nesli Basgoz sold 1,889 shares of the business’s stock in a transaction on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total value of $416,430.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.36% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC. (NYSE:AGN).

Institutional Ownership by Quarter for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.